{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T18:57:11Z","timestamp":1725821831435},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.ctrv.2012.05.007","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T20:53:53Z","timestamp":1339707233000},"page":"340-349","source":"Crossref","is-referenced-by-count":9,"title":["Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"given":"Teruhiko","family":"Terasawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos A.","family":"Trikalinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Djulbegovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Trikalinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2012.05.007_b0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2012.05.007_b0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.05.007_b0015","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","article-title":"Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.05.007_b0020","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","article-title":"Chronic lymphocytic leukaemia","volume":"371","author":"Dighiero","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.05.007_b0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/asheducation-2007.1.324","article-title":"Comprehensive management of the CLL patient: a holistic approach","volume":"2007","author":"Shanafelt","year":"2007","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1016\/j.ctrv.2012.05.007_b0305","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2012.05.007_b0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ctrv.2006.05.002","article-title":"Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis","volume":"32","author":"Steurer","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2012.05.007_b0310","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.2011.053512","article-title":"Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials","volume":"97","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2012.05.007_b0045","unstructured":"National Comprehensive Cancer Network. Non-Hodgkin\u2019s Lymphomas, Version 2.2012. NCCN Clinical Practice Guidelines in Oncology. 2012."},{"issue":"Suppl. 6","key":"10.1016\/j.ctrv.2012.05.007_b0315","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdr377","article-title":"Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Eichhorst","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl. 7","key":"10.1016\/j.ctrv.2012.05.007_b0320","doi-asserted-by":"crossref","first-page":"vii154","DOI":"10.1093\/annonc\/mdq373","article-title":"Chronic lymphocytic leukemia","volume":"21","author":"Hallek","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0060","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","article-title":"Update on therapy of chronic lymphocytic leukemia","volume":"29","author":"Gribben","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0065","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2012.05.007_b0070","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2012.05.007_b0075","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ije\/31.1.150","article-title":"Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed","volume":"31","author":"Robinson","year":"2002","journal-title":"Int J Epidemiol."},{"key":"10.1016\/j.ctrv.2012.05.007_b0325","first-page":"CD004270","article-title":"Purine antagonists for chronic lymphocytic leukaemia","volume":"3","author":"Steurer","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2012.05.007_b0085","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/02841860151116303","article-title":"A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia","volume":"40","author":"Kimby","year":"2001","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0090","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1080\/10428190412331283260","article-title":"Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"45","author":"Zhu","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2012.05.007_b0095","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.05.007_b0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.ctrv.2012.05.007_b0105","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. 2008.","DOI":"10.1002\/9780470712184"},{"key":"10.1016\/j.ctrv.2012.05.007_b0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Dersimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ctrv.2012.05.007_b0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2012.05.007_b0330","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2012.05.007_b0125","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2012.05.007_b0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu","year":"2006","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ctrv.2012.05.007_b0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0140","first-page":"429","article-title":"A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C","volume":"30","author":"Montserrat","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0335","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood.V75.7.1422.1422","article-title":"A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia","volume":"75","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.05.007_b0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10428199109103385","article-title":"Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (PETHEMA) trials","volume":"5","author":"Montserrat","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2012.05.007_b0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/10428199109103386","article-title":"Chlorambucil\/prednisone versus CHOP in symptomatic chronic lymphocytic leukemias of B-cell type: a randomized trial","volume":"5","author":"Kimby","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2012.05.007_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/10428199109103389","article-title":"CLL trials in the United Kingdom: the Medical Research Council CLL Trials 1, 2 and 3","volume":"5","author":"Catovsky","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2012.05.007_b0165","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.1991.9.5.770","article-title":"Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial","volume":"9","author":"Raphael","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/10428199109103387","article-title":"CHOP versus chlorambucil + prednisolone in chronic lymphocytic leukemia","volume":"5","author":"Hansen","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2012.05.007_b0340","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/10428199409049634","article-title":"Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia","volume":"13","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2012.05.007_b0180","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2107::AID-CNCR7>3.0.CO;2-L","volume":"79","author":"Jaksic","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.05.007_b0345","article-title":"UK Medical Research Council CLL3 \u2013 A randomized trial of the addition of epirubicin to standard chlorambucil treatment","author":"Catovsky","year":"2000","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.05.007_b0190","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.05.007_b0350","article-title":"Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with Chronic Lymphocytic Leukemia (CLL) [abstract]","author":"Rai","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.05.007_b0200","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.05.007_b0205","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.05.007_b0210","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial","volume":"96","author":"Robak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.05.007_b0215","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0220","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0225","first-page":"2449","volume":"116","author":"Knauf","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.05.007_b0230","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.05.007_b0355","first-page":"290","article-title":"Fludarabine and cyclophosphamid (Fc) Versus cyclophosphamide, vincristine and prednisone (Cvp) As first line treatment in chronic lymphocytic leukaemia (Cll) [abstract]","author":"Abdelhamid","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2012.05.007_b0365","first-page":"599","article-title":"Fludarabine and cyclophosphamide (fc) versus cyclophosphamide, vincristine and prednisone (cvp) as first line therapy in Chronic Lymphocytic Leukemia (CLL) [abstract]","volume":"94","author":"Ionita","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2012.05.007_b0245","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.05.007_b0250","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0255","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.05.007_b0260","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.2009.25.9630","article-title":"Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.05.007_b0370","article-title":"Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in b-cell chronic lymphocytic leukemia [abstract]","author":"Reynolds","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.05.007_b0270","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2005-12-4828","volume":"108","author":"Robak","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.05.007_b0275","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.291.20.2457","article-title":"Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles","volume":"291","author":"Chan","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2012.05.007_b0280","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1749-6632.1993.tb26343.x","article-title":"Publication bias: the problem that won\u2019t go away","volume":"703","author":"Dickersin","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2012.05.007_b0285","doi-asserted-by":"crossref","first-page":"b1147","DOI":"10.1136\/bmj.b1147","article-title":"Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews","volume":"338","author":"Song","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2012.05.007_b0290","unstructured":"Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: The National Academies Press; 2011."},{"key":"10.1016\/j.ctrv.2012.05.007_b0295","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMp0905631","article-title":"Comparative-effectiveness research\u2013implications of the Federal Coordinating Council\u2019s report","volume":"361","author":"Conway","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.05.007_b0300","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMp0903496","article-title":"Comparative effectiveness\u2013thinking beyond medication A versus medication B","volume":"361","author":"Volpp","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212001302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212001302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T03:38:12Z","timestamp":1594265892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737212001302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0305737212001302"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.05.007","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}